Dare Bioscience cancels development pipeline including Single-Use Diagnostics
Dare Bioscience cancelled its Single-Use Diagnostics pipeline and intends to pursue strategic alternatives for its portfolio, signaling a shift in its corporate focus.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed